Compare Merck & Co., Inc. (MRK) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Merck & Co., Inc. trades at $146.1 (market cap $351.28B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.77 (market cap $17.53B). The key difference: Merck & Co., Inc. is far larger — about 20× iShares Broad USD Investment Grade Corporate Bond's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares Broad USD Investment Grade Corporate Bond pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| MRK | USIG | |
|---|---|---|
Market Cap | $351.28B | $17.53B |
Volume | 7,969,665 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $52.69 |
52-Week Low | $82.49 | $48.54 |
Typical Hold Time | 98 Days | 44 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
USIG trades at $48.765 with minimal daily movement (+0.17%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces resistance at $49 levels while finding support at $48. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon's increased stake, indicating institutional confidence.
The bearish technical setup contrasts with institutional accumulation, creating a divergence worth monitoring. Key risks include market volatility and competitive pressures in the investment grade corporate bond ETF space. The absence of current fundamental metrics requires careful due diligence on underlying bond portfolio quality and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
